Boston Scientific closes acquisition of Symetis for $435M

Boston Scientific completed its acquisition of Symetis SA, a Swiss TAVI device company, for $435 million in cash, expanding its structural heart portfolio.

“The acquisition expands Boston Scientific’s structural heart portfolio and Symetis will join the Boston Scientific Interventional Cardiology division.”jdsupra.com

• 1 source
• jdsupra.comBoston Scientific closes acquisition of TAVI device company, Symetis | Knobbe Martens - JDSupraJun 3, 2017

Summarized from public sources; check the original articles before acting on it.